Ixchiq Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Ixchiq market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the increasing prevalence of chikungunya, rising temperatures and changing weather patterns, enhanced public health campaigns, government initiatives, and growing healthcare expenditure.

Future market growth is expected to be driven by support from global health organizations, rising urbanization, increased investment in vaccine research and development, favorable international health regulations and policies, and the growth in international travel. Key trends in the forecast period include the development of combination vaccines, technological advancements, a shift toward preventive healthcare, the integration of telemedicine services for remote chikungunya management, and the expansion of vaccine coverage.

The increasing prevalence of chikungunya is expected to drive the growth of the ixchiq market in the future. Chikungunya is a viral disease spread by Aedes mosquitoes, characterized by symptoms such as fever and severe joint pain, with outbreaks primarily occurring in tropical and subtropical regions. The rise in chikungunya cases can be attributed to factors such as climate change, growing urbanization, and changes in mosquito populations, which expand the regions suitable for the virus's transmission. Ixchiq helps manage chikungunya symptoms by reducing inflammation and pain, alleviating joint pain and fever caused by the virus. For example, in May 2023, The American Society of Plastic Surgeons (ASPS), a US-based organization, reported that chikungunya cases in the Americas increased from 137,025 in 2021 to 271,130 in 2022, reflecting a 98% rise from the previous year. As a result, the growing prevalence of chikungunya is fueling the growth of the ixchiq market.

The growing investments in vaccine research and development are expected to further propel the ixchiq market. Vaccine research and development involves innovating, testing, and producing vaccines to prevent or treat diseases through laboratory research, clinical trials, and regulatory approvals to ensure safety and effectiveness. The rising investments in this area are driven by the need to address emerging diseases and improve public health. These investments support the ixchiq vaccine by funding advanced research, improving its efficacy, and accelerating its production for better chikungunya prevention. For instance, in February 2022, the Department of Health and Social Care, a UK-based government department, announced a UK aid funding of $12.75 million (£10 million) to support research into vaccines for combating deadly diseases in low- and middle-income countries. Therefore, the increasing focus on vaccine research and development is expected to stimulate the growth of the ixchiq market.

A key trend in the ixchiq market is the development of the chikungunya vaccine, which is set to drive significant progress in the field. A chikungunya vaccine is designed to provide immunity against the chikungunya virus, which is primarily transmitted by mosquito bites. For example, in July 2024, Valneva SE, a France-based biotechnology company, received marketing authorization from the European Commission for IXCHIQ, the world’s first chikungunya vaccine. Approved for individuals aged 18 and older, it is the only licensed vaccine for chikungunya, addressing the growing public health threat of frequent outbreaks of this mosquito-borne disease in Europe. The approval was supported by data from a pivotal Phase 3 clinical trial published in *The Lancet*, which showed a 98.9% seroresponse rate 28 days after vaccination, with this immune response sustained for 24 months in 97% of participants.

The key company operating in the ixchiq market is Valneva SE.

North America was the largest region in the ixchiq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ixchiq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ixchiq market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

IXCHIQ is a vaccine granted accelerated approval for the prevention of chikungunya virus (CHIKV) in adults aged 18 and older who are at increased risk of exposure. The approval is based on anti-CHIKV neutralizing antibody levels, with continued approval dependent on confirmatory studies demonstrating clinical benefit.

The primary patient groups for ixchiq include pediatric patients, adult patients, and high-risk individuals. Pediatric patients are those under the age of 18. The use of IXCHIQ in pediatric patients involves administering the vaccine to address specific medical needs, taking into account their unique physiology and clinical requirements as determined by a healthcare provider. It is used for purposes such as preventing bleeding episodes and providing surgical prophylaxis, and is available through various distribution channels, including hospitals, specialty clinics, pharmacies, and online pharmacies.

The ixchiq market research report is one of a series of new reports that provides ixchiq market statistics, including the ixchiq industry's global market size, regional shares, competitors with an ixchiq market share, detailed ixchiq market segments, market trends and opportunities, and any further data you may need to thrive in the ixchiq industry. This ixchiq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ixchiq market consists of sales of vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.